9/29/2016
WHAT: The University of Pittsburgh Cancer Institute (UPCI) will host the first Invasive Lobular Carcinoma (ILC) International Symposium. Clinical experts will explore ILC, the second most common type of breast cancer and the eighth most common cancer in women. The goal is to begin the process of leading research that will ultimately result in improved outcomes for patients with this disease.
WHY: ILC often is difficult to diagnose since it typically does not cause a firm or distinct breast lump. Clinical and laboratory studies of breast cancer have focused almost exclusively on the more common invasive ductal cancers (IDC). There has never been a focused meeting to discuss basic, translational and clinical research on ILC, which affects nearly 30,000 women each year.
WHO:
• Steffi Oesterreich, Ph.D.
Professor of Pharmacology & Chemical Biology
Director of Education, Women’s Cancer Research Center
Director, UPCI Academy
Chair, 1st International ILC Symposium
• Nancy E. Davidson, M.D.
Director, University of Pittsburgh Cancer Institute
Associate vice chancellor for Cancer Research
Hillman Professor of Oncology
Distinguished professor of Medicine and Pharmacology & Chemical Biology
Co-Chair, 1st International ILC Symposium
• Otto Metzger, M.D.
Medical oncologist, Dana Farber Cancer Institute, Boston
Co-Chair, 1st International ILC Symposium
• Heather Hillier
Breast Cancer Advocate
Co-Chair, 1st International ILC Symposium
• More than 30 of the world’s leading ILC researchers and 20 ILC survivors
WHEN and WHERE:
Thursday, Sept. 29
Herberman Conference Center at UPMC Cancer Pavilion
Second floor
5150 Centre Ave.
Pittsburgh, 15232
Friday, Sept. 30
Cooper Classrooms in the Hillman Cancer Center
Ground floor
5115 Centre Ave.
Pittsburgh, 15232
